viewProNAi Therapeutics

ProNAi eases back after almost doubling in trading debut

ProNAi is pioneering a novel class of therapeutics based on our proprietary DNA interference (DNAi) technology platform.

Shares of ProNAi Therapeutics (NASDAQ:DNAI) fell a day after the clinical-stage oncology company made its trading debut following an initial public offering.

ProNAi surrendered 2.5 percent to $30.05 at 2:37 p.m. in New York. The shares almost doubled to as high as $33.75 in its trading debut yesterday.

The cancer-drug company raised $137.7 million by selling 8.1 million shares at $17 a share.

The offering followed the July 2 IPO of venture-backed diagnostics company Natera Inc., whose market value has since reached $1 billion.

ProNAi’s top venture investors included Vivo Capital, Frazier Healthcare, OrbiMed Advisors and Adams Street Partners. The Vancouver-based company trades on the Nasdaq under the ticker symbol DNAI.

Jefferies LLC and BofA Merrill Lynch acted as joint book-running managers for the offering. BofA Merrill Lynch is also serving as ProNAi's Strategic IPO Advisor. Wedbush PacGrow and SunTrust Robinson Humphrey acted as co-managers.

ProNAi is pioneering a novel class of therapeutics based on our proprietary DNA interference (DNAi) technology platform. 

The company’s lead DNAi product candidate, PNT2258, targets BCL2, a widely overexpressed oncogene that is an important gatekeeper of the programmed cell death process known as apoptosis and has been linked to many forms of cancer. 


Quick facts: ProNAi Therapeutics

Price: - -

Market: NASDAQ
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Protech Home Medical has a full treasury as they look for rapid growth in...

Protech Home Medical (CVE: PTQ- OTCQX: PTQQF) CEO Greg Crawford joined Steve Darling from Proactive to discuss the home medical equipment industry company. That company provides devices like ventilators and oxygen concentrators. Crawford told Proactive the company just completed a large...

8 hours, 24 minutes ago

2 min read